FDA Releases Draft Guidance for Cancer Drug and Biological Products Clinical Data

Summary

The Food and Drug Administration (FDA) has made available a draft guidance document outlining recommendations for collecting and submitting clinical data to support marketing claims for cancer treatments in new drug applications, biologics license applications, and supplemental indications.